Immunology

Latest News

Stressed older woman | Image credit: InsideCreativeHouse – stock.adobe.com
Musculoskeletal Disorders in Postmenopausal Women Are Rising Worldwide

June 24th 2025

Osteoarthritis leads the burden, projected to affect 50% of postmenopausal women by 2045.

FDA building sign | Image credit: Tada Images – stock.adobe.com
FDA Approves At-Home Belimumab Autoinjector for Pediatric Lupus Nephritis

June 24th 2025

Rheumatoid arthritis in hand | Image credit: yodiyim – stock.adobe.com
Subcutaneous Tocilizumab Superior to Methotrexate in Chinese Patients With RA

June 12th 2025

AChR-Ab titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study. | Image credit: luchschenF - stock.adobe.com
AChR-Ab Titers Associated With Myasthenia Gravis Severity

February 21st 2025

Hidradenitis suppurativa. | Image Credit: MdBabul - stock.adobe.com
Bimekizumab for Hidradenitis Suppurativa Offers Durable Disease Control in Long-Term Data

February 13th 2025

More News

Findings suggest checking regular radiographs in clinical practice for loss of bone density or VFs can be helpful in managing axial spondyloarthritis. - Mutshino_Artwork - stock.adobe.com
August 16th 2024

Long-Term TNFi Treatment for AxSpA Improved, Maintained Bone Mineral Density

Rose McNulty
Lumbar spine bone mineral density improved significantly and was maintained during long-term tumor necrosis factor inhibitor (TNFi) treatment for axial spondyloarthritis.
AJMC
August 15th 2024

Geographic Variability of Medicaid Acceptance Among Allergists in the US

Frances O. Ho, MD Chaoyi Zheng, MS Mech Frazier, MA Sai R. Nimmagadda, MD Ruchi S. Gupta, MD, MPH Lucy A. Bilaver, PhD
The proportion of allergists accepting Medicaid in the US varied significantly among and within states.
Disease control was linked with better quality of life among patients with psoriatic arthritis. | Image credit: Evrymmnt - stock.adobe.com
August 9th 2024

Clinical Disease Control in Psoriatic Arthritis Improves Quality of Life

Lana Pine
Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.
Rheumatoid arthritis | Image: LinkedIn
August 5th 2024

Understanding Inflammatory Pathways to Address CV Risk in Patients With Autoimmune Disease

Mary Caffrey
A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.
In the pooled analysis, ankylosing spondylitis was associated with a greater risk of cancer occurrence. | Image credit: Lila Patel - stock.adobe.com
July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty
The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.
myasthenia gravis | Image Credit: Николай Зотов-stock.adobe.com
July 21st 2024

Chinese Patients With gMG Respond Well to Efgartigimod

Jared Kaltwasser
A new report offers safety and efficacy data on a population with generalized myasthenia gravis (gMG) not represented in the drug’s pivotal phase 3 trial.
Arthritis in hands - stockdevil - stock.adobe.com
July 20th 2024

Persistently Active Rheumatoid Arthritis Linked With Socioeconomic Factors

Lana Pine
Factors independently associated with persistently active RA included age, gender, previous or current smoking status, and social deprivation.
The review identified several challenges to quality rheumatoid arthritis treatment, along with potential interventions to improve care. | Image Credit: MicroOne - stock.adobe.com
July 18th 2024

Gaps in Rheumatoid Arthritis Care Quality Exist in North America

Rose McNulty
A literature review plus in-person visits helped identify barriers to quality rheumatoid arthritis care, as well as effective interventions to improve care quality.
Book about myasthenia gravis | Image Credit: mdaros-stock.adobe.com
July 16th 2024

Promising Results for Efgartigimod in Myasthenic Crisis

Kimberly Rath, PharmD
A new case report details the successful use of efgartigimod as a rescue medication in a patient with therapy-refractory myasthenic crisis.
Physical therapy on treadmill | Image credit: Justlight - stock.adobe.com
July 9th 2024

Exercise Therapy Can Reduce Symptoms, Disease Activity in Axial Spondyloarthritis

Rose McNulty
Patients with axial spondyloarthritis who took part in exercise therapy showed improvements in disease activity and symptoms compared with patients who did not, a meta-analysis found.
Patient rubbing sore hands with rheumatoid arthritis | Image credit: Evrymmnt - stock.adobe.com
July 3rd 2024

Patient-Reported Pain Improvement Linked With Remission in Rheumatoid Arthritis

Rose McNulty
Pain improvement was associated with remission or low disease activity in patients undergoing treatment for rheumatoid arthritis, a study found.
Obesity was linked with worse patient-reported pain outcomes in rheumatoid arthritis. | Image credit: 9nong - stock.adobe.com
July 1st 2024

Obesity Linked to Worse Patient-Reported Outcomes in Rheumatoid Arthritis

Abigail Brooks, MA
Patients with rheumatoid arthritis and obesity exhibited worse scores for subjective measures like pain and fatigue compared with those without obesity.
Spine MRI - Kondor83 - stock.adobe.com
June 29th 2024

Preexisting Structural Damage, Inflammation Linked With Radiographic Progression in Patients Treated for AxSpA

Rose McNulty
Preexisting spinal damage and higher levels of inflammatory activity at baseline were linked with radiographic progression in axial spondyloarthritis treated with biologic disease-modifying antirheumatic drugs over 2 years regardless of treatment type.
Bimekizumab demonstrated safety and efficacy at 2 years among patients with nr-axSpA and AS. - natali_mis - stock.adobe.com
June 28th 2024

Bimekizumab Shows Long-Term Efficacy in Nonradiographic AxSpA, Ankylosing Spondylitis

Rose McNulty
Bimekizumab demonstrated safety and efficacy at 2 years among patients with nonradiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).
Back pain due to spondyloarthritis- fizkes - stock.adobe.com
June 22nd 2024

AxSpA Treatment Intensification in Practice Linked With Higher ASDAS Cutoff Than Recommended

Rose McNulty
In the clinical practice setting, intensifying treatment for axial spondyloarthritis (axSpA) is associated with a higher Ankylosing Spondylitis Disease Activity Score (ASDAS) cutoff value than recommended, new research found.
Efgartigimod alfa and hyaluronidase is now FDA approved for the treatment of adults with CIDP. | Image credit: wladimir1804 - stock.adobe.com
June 21st 2024

FDA Approves Efgartigimod Alfa and Hyaluronidase for CIDP

Rose McNulty
The FDA today approved efgartigimod alfa and hyaluronidase-qvfc for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis
June 11th 2024

Sarilumab FDA Approved for Active Polyarticular Juvenile Idiopathic Arthritis

Rose McNulty
The approval brings a new treatment option to pediatric patients with polyarticular juvenile idiopathic arthritis, which is a form of arthritis affecting multiple joints at the same time.
Woman with back pain | Image credit: vectorfusionart - stock.adobe.com
June 7th 2024

Study Suggests TNF Inhibitor Use Is Cardioprotective in Radiographic Axial Spondyloarthritis

Rose McNulty
Tumor necrosis factor (TNF) inhibitor use was associated with a lower risk of cardiovascular outcomes in patients with radiographic axial spondyloarthritis in a recent study.
Woman sleeping next to alarm clock | Image credit: stokkete - stock.adobe.com
May 31st 2024

Pain Linked With Poor Sleep Quality, Comorbidities in RA, PsA

Rose McNulty
Among patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), intense pain symptoms were associated with poor sleep, fibromyalgia, depression, and sleep apnea.
Blood analysis | Image credit: Parilov-stock.adobe.com
May 31st 2024

Novel Serum Biomarkers Show Potential for Diagnosing, Monitoring Axial Spondyloarthritis

Rose McNulty
A recent review highlighted several candidate biomarkers for diagnosing axial spondyloarthritis associated with inflammatory bowel disease in early phases.
Concept of hidradenitis suppurativa | Image credit: syahrir - stock.adobe.com
May 24th 2024

Bimekizumab Elicits Clinically Meaningful Responses in Moderate to Severe Hidradenitis Suppurativa

Rose McNulty
Newly published findings from the pivotal phase 3 BE HEARD I and BE HEARD II trials demonstrated that bimekizumab was well tolerated and produced clinically meaningful responses in patients with moderate to severe hidradenitis suppurativa.
Drug costs | Image credit: nikitos - stock.adobe.com
May 20th 2024

IQVIA Report Highlights Shifts in Medicine Use, Spending Across Therapy Areas

Rose McNulty
Areas of focus in the annual report included health system utilization and recovery from the pandemic, patterns of medicine use, drug pricing, and patient out-of-pocket costs.
Document with denied - G_stockerthailand - stock.adobe.com
May 10th 2024

Research Shows Prior Authorization Denials Delay Critical Immunology Care

Giuliana Grossi
Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Young Woman Sitting | Image Credit: Bungon - stock.adobe.com
May 3rd 2024

Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis

Giuliana Grossi
Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Man Feeling Back Pain | Image Credit: Mantinov - stock.adobe.com
April 30th 2024

Bimekizumab Shows Sustained Efficacy in Treating Axial Spondyloarthritis for 52 Weeks

Giuliana Grossi
Results from a study presented at the Academy of Managed Care Pharmacy 2024 annual meeting demonstrated sustained efficacy of bimekizumab compared with placebo in patients with non-radiographic and radiographic axial spondyloarthritis (axSpA) at week 52.
Brain illustration in blue and pink | Image credit: jolygon - stock.adobe.com.jpg
April 17th 2024

Cognitive Impairment Screening in the Clinic for Patients With SLE

Laura Joszt, MA
Screening for cognitive impairment among patients with systemic lupus erythematosus (SLE) can be challenging; however, some shorter assessments have shown promise for use in the clinical setting.
White plastic bottle with medical pills | Image Credit: encierro - stock.adobe.com
April 12th 2024

NSAIDs vs bDMARDs: Sex Disparities in Treatment Initiation for Axial Spondyloarthritis

Giuliana Grossi
New research examining treatment initiation patterns among patients with axial spondyloarthritis revealed significant sex-based disparities, shedding light on the process from diagnosis to therapeutic intervention.
Woman sitting on bed with back pain illustrated by a highlighted spine | Image credit: WavebreakMediaMicro - stock.adobe.com
April 12th 2024

Radiographic Progression Low for High-Risk Patients With axSpA on Both Secukinumab and an Adalimumab Biosimilar

Kimberly Rath, PharmD
Patients with radiographic axial spondyloarthritis (ax-SpA) and a high risk of radiographic progression had similar low progression on both secukinumab and an adalimumab biosimilar.
Hand with psoriatic arthritis | Image credit: Iri-s - stock.adobe.com.jpg
April 4th 2024

Indirect Comparison Finds Bimekizumab More Effective Than Guselkumab in Psoriatic Arthritis

Laura Joszt, MA
Patients included in the analysis had psoriatic arthritis and had either not been treated with biologic disease-modifying antirheumatic drugs or had an inadequate response or an intolerance to tumor necrosis factor inhibitors.
Wooden blocks spelling biosimilar | Image credit: lexiconimages - stock.adobe.com
March 29th 2024

Data Support Safety, Efficacy of Biosimilar-to-Biosimilar Switching

Laura Joszt, MA
The majority of studies evaluating biosimilar-to-biosimilar switching were for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo